Mettler-Toledo International Inc. (MTD), headquartered in Columbus, Ohio, manufactures and supplies precision instruments and services for laboratory, industrial, and food retailing applications. Valued at $28 billion by market cap, the company also supplies several related analytical and measurement technologies.

Shares of this leading precision instruments supplier have underperformed the broader market over the past year. MTD has gained 5.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 13%. In 2026, MTD stock is down 1.2%, compared to the SPX’s marginal rise on a YTD basis.

If Palantir is Near a Bottom, What's the Best Play in PLTR Stock?

NVDA Earnings, Tariffs and Other Key Things to Watch this Week

Adobe (ADBE) Stock Has Been Beaten Up But the Smart Money Remains Resilient

Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.

Narrowing the focus, MTD’s outperformance is apparent compared to the First Trust Indxx Global Medical Devices ETF (MDEV). The exchange-traded fund has declined about 3% over the past year. Moreover, MTD’s dip on a YTD basis outshine the ETF’s 1.4% losses over the same time frame.

On Feb. 5, MTD shares closed down marginally after reporting its Q4 results. Its adjusted EPS of $13.36 surpassed Wall Street expectations of $12.76. The company’s revenue was $1.13 billion, topping Wall Street forecasts of $1.10 billion. The company expects full-year adjusted EPS in the range of $46.05 to $46.70.

For fiscal 2026, ending in December, analysts expect MTD’s EPS to grow 8.7% to $46.46 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.

Among the 14 analysts covering MTD stock, the consensus is a “Moderate Buy.” That’s based on six “Strong Buy” ratings, and eight “Holds.”

This configuration is more bullish than three months ago, with five analysts suggesting a “Strong Buy.”

On Feb. 10, Morgan Stanley (MS) analyst Kallum Titchmarsh maintained a “Hold” rating on MTD and set a price target of $1,475, implying a potential upside of 7.1% from current levels.

The mean price target of $1,513.69 represents a 9.9% premium to MTD’s current price levels. The Street-high price target of $1,700 suggests an upside potential of 23.4%.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com